• The result of pathological biopsy showed esophageal squamous cell carcinoma;

• Have not received systemic or local treatment for esophageal cancer in the past;

• Age 18-75 years (including 18 and 75 years old), both male and female;

• ECOG score 0-1;

• Thoracic esophageal cancer assessed by CT/MRI/PET-CT etc. as resectable and the clinical stage is T1b-3N1-3M0 or T3N0M0, according to the 8th edition of AJCC staging;

• Those who are expected to achieve R0 resection;

• Voluntarily sign an informed consent form before treatment;

• Plan to receive surgical treatment after neoadjuvant treatment is completed;

• No surgical contraindications;

⁃ Normal function of major organs

⁃ Female subjects with fertility must undergo a serum pregnancy test within 72 hours before starting the study drug administration, and the result is negative, and take effective contraception during the trial and at least 3 months after the last administration Measures (such as intrauterine devices, contraceptives, or condoms); for male subjects whose partners are females of childbearing age, effective contraceptive measures should be taken during the trial and within 3 months after the last administration;

⁃ The subjects have good compliance and can follow up the efficacy and adverse events/reactions according to the requirements of the plan;